These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Desferrioxamine versus erythropoietin for treatment of dialysis anaemia. Padovese P; Gallieni M; Galmozzi C; Brancaccio D Lancet; 1990 Jun; 335(8703):1465. PubMed ID: 1972238 [No Abstract] [Full Text] [Related]
6. Microcytic anemia in dialysis patients. Grossman SD; Smith LE Am J Kidney Dis; 1988 Apr; 11(4):362. PubMed ID: 3354574 [No Abstract] [Full Text] [Related]
7. Improvement in the erythropoiesis of chronic haemodialysis patients with desferrioxamine. de la Serna FJ; Praga M; Gilsanz F; Rodicio JL; Ruilope LM; Alcazar JM Lancet; 1988 May; 1(8593):1009-11. PubMed ID: 2896866 [TBL] [Abstract][Full Text] [Related]
8. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis]. Simon P Nephrologie; 1986; 7(5):177-80. PubMed ID: 3822038 [No Abstract] [Full Text] [Related]
9. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia]. Stojimirović B; Grujić-Adanja G Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238 [TBL] [Abstract][Full Text] [Related]
10. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine. Mudde AH; Roodvoets AP; Van Groningen K Neth J Med; 1985; 28(1):6-11. PubMed ID: 3974771 [No Abstract] [Full Text] [Related]
11. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy. Milne FJ; Sharf B; Bell P; Meyers AM Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027 [TBL] [Abstract][Full Text] [Related]
12. Clearance of aluminum by hemodialysis: effect of desferrioxamine. Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984 [No Abstract] [Full Text] [Related]
13. rHuEpo-resistant anaemia in haemodialysis patients. Ozono Y; Harada T; Taura K; Kawatomi M; Hara K Nephrol Dial Transplant; 1994; 9(7):872-4. PubMed ID: 7970133 [No Abstract] [Full Text] [Related]
14. Treatment of hemodialysis hemosiderosis with desferrioxamine. Rembold CM; Krumlovsky FA; Roxe DM; Fitzsimmons E; del Greco F Trans Am Soc Artif Intern Organs; 1982; 28():621-6. PubMed ID: 7164314 [No Abstract] [Full Text] [Related]
15. Respective role of haemosiderosis and desferrioxamine therapy in the risk from infection of haemodialysed patients. Tielemans C; Lenclud C Q J Med; 1988 Jul; 68(255):573-4. PubMed ID: 3252307 [No Abstract] [Full Text] [Related]
16. The response of the normochromic normocytic anaemia of chronic renal failure to desferrioxamine. O'Brien AA; Moore DP; Keogh JA Ir J Med Sci; 1987 Aug; 156(8):236-7. PubMed ID: 3667188 [No Abstract] [Full Text] [Related]
17. Role of desferrioxamine in the treatment of dialysis encephalopathy. Ackrill P; Ralston AJ; Day JP Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985 [No Abstract] [Full Text] [Related]
18. [Effect of fluoxymesterone on anaemia in chronic haemodialysis--special reference to combination therapy with iron (author's transl)]. Kataoka Y Horumon To Rinsho; 1981 Jun; 29(6):675-82. PubMed ID: 7318194 [No Abstract] [Full Text] [Related]
19. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Chan D; Irish A; Dogra G Nephrology (Carlton); 2005 Aug; 10(4):336-40. PubMed ID: 16109077 [TBL] [Abstract][Full Text] [Related]
20. [Renal anemia and the effect of long-term dialysis]. Opatrná S; Opatrný K Cas Lek Cesk; 1999 Feb; 138(4):107-10. PubMed ID: 10376407 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]